LENSAR Inc. (NASDAQ: LNSR) is a prominent player in the medical technology sector, focusing on advanced robotic laser solutions for cataract treatment. The company is set to release its quarterly earnings on March 19, 2026. Wall Street anticipates an earnings per share (EPS) of approximately -$0.06, with projected revenue around $20.3 million.
Recently, LNSR's stock faced a decline after Alcon AG (NYSE: ALC) terminated their merger agreement. Initially, Alcon planned to acquire LENSAR for $14.00 per share, valuing the deal at about $356 million. However, regulatory hurdles, particularly from the Federal Trade Commission, led to the merger's cancellation.
Despite the setback, LENSAR retains a $10 million deposit from the merger agreement. Financially, the company faces challenges, with a negative price-to-earnings (P/E) ratio of -1.66 and a negative earnings yield of -60.17%. These figures indicate that LNSR is currently not profitable.
LNSR's financial metrics reveal more insights. The price-to-sales ratio is approximately 1.44, meaning investors pay $1.44 for every dollar of sales. The enterprise value to sales ratio is about 1.36, showing a similar valuation. However, the enterprise value to operating cash flow ratio is -6.80, highlighting financial difficulties.
On a positive note, LNSR maintains a current ratio of 1.24, suggesting it has enough current assets to cover its current liabilities. Despite a debt-to-equity ratio of -0.24, indicating more liabilities than equity, the company continues to navigate its financial landscape.
